Harinoor Mann, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,196 of the $4,797 with a category attached, or 87.5%. It is spread thinly across 34 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,553, 2.8 times the $564 reported in 2019.
Across 168 payments — averaging $28.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ceribell, Inc.$572
- AstraZeneca$571
- AbbVie$560
- Livanova USA, Inc.$309
- Pfizer$270
- Novartis$260
- plus $2K from 28 others
What the payments were for
- Travel & lodging$50010%
- Food & beverage$4,19687%
- Education$1012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ceribell, Inc. | 2 | $572 |
| AstraZeneca(2 entities) | 16 | $571 |
| AbbVie | 40 | $560 |
| Livanova USA, Inc. | 3 | $309 |
| Pfizer | 15 | $270 |
| Novartis | 7 | $260 |
| UCB, Inc. | 5 | $213 |
| Genentech USA, Inc. | 12 | $209 |
| Vanda Pharmaceuticals Inc. | 9 | $188 |
| Axsome Therapeutics, Inc. | 9 | $168 |
| Lilly USA, LLC | 6 | $152 |
| SK Life Science, Inc. | 2 | $135 |
| Sanofi | 1 | $125 |
| Stryker | 1 | $110 |
| Biohaven Pharmaceuticals, Inc. | 1 | $105 |
| Teva Pharmaceuticals USA, Inc. | 6 | $100 |
| Argenx US, Inc. | 4 | $100 |
| Averitas Pharma Inc. | 3 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| Eisai Inc. | 3 | $75 |
| Neurocrine Biosciences, Inc. | 3 | $58 |
| Amneal Pharmaceuticals LLC | 3 | $58 |
| Impel Pharmaceuticals LLC | 2 | $43 |
| Tanabe Pharma America, Inc. | 2 | $35 |
| TG Therapeutics, Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $27 |
| Cycle Pharmaceuticals Inc | 1 | $24 |
| Biogen | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Bristol Myers Squibb | 1 | $21 |
| Amylyx Pharmaceuticals, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ceribell Rapid Response EEG$500
- MAYZENT$122
- SOLIRIS$121
- XCOPRI$117
- VNS - Sentiva$111
- AXSOS$110
- VNS Therapy$106
- NURTEC ODT$105
- Briviact$104
- ULTOMIRIS$100
How this compares
$4,797 in reported general payments places this provider in the 65th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 24 | $404,845 |
| Kesimpta PenOfatumumab | 23 | $222,272 |
| Nurtec OdtRimegepant Sulfate | 127 | $133,821 |
| UbrelvyUbrogepant | 85 | $97,622 |
| RytaryCarbidopa/Levodopa | 33 | $58,445 |
| Emgality PenGalcanezumab-Gnlm | 39 | $38,126 |
| QuliptaAtogepant | 24 | $34,850 |
| BotoxOnabotulinumtoxina | 23 | $27,942 |
| MysolinePrimidone | 13 | $25,367 |
| NeuproRotigotine | 29 | $22,367 |
| Aimovig AutoinjectorErenumab-Aooe | 22 | $20,798 |
| EliquisApixaban | 22 | $15,652 |
| ZavzpretZavegepant Hcl | 11 | $11,747 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 158 | $3,884 |
| Memantine Hcl | 44 | $3,688 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $79 | $404,84524 claims |
| PfizerNurtec Odt, Eliquis, Zavzpret | $270 | $161,219160 claims |
| AbbVieUbrelvy, Qulipta, Botox | $560 | $160,414132 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $58 | $59,62352 claims |
| UCB, Inc.Neupro | $213 | $22,36729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 702 neurology providers in Ohio.
Other neurology in Akron
- Aram ZabetiCincinnati$1.6M
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Martin TaylorNew Albany$821K
- Jacqueline NicholasColumbus$743K
- Lawrence ElmerToledo$687K
- Kenneth PugarCenterville$582K
- Brendan BauerSheffield Village$548K
- Geoffrey EubankColumbus$508K
- Lawrence GoldstickDayton$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.